# MOTS-c: an equal opportunity insulin sensitizer.

> PubMed lists PMID 30788534 in Journal of molecular medicine (Berlin, Germany) as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-02-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30788534-mots-c:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-10-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30788534-mots-c/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30788534-mots-c-v1.json
- Content SHA-256: `ec7c699ec4d4fc1570d20b2d26b050ccfaaf8911472cba2cd87a4f4b7769878f`

## Claims and source pins

### Headline

MOTS-c: an equal opportunity insulin sensitizer. ([`pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9`](#source-pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9))

### Summary

PubMed lists PMID 30788534 in Journal of molecular medicine (Berlin, Germany) as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-02-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9`](#source-pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9))

### Paragraph 1

PubMed lists PMID 30788534 in Journal of molecular medicine (Berlin, Germany) as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-02-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9`](#source-pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9`](#source-pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9))

## Sources

<a id="source-pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9"></a>
- **MOTS-c: an equal opportunity insulin sensitizer. · retained source version 1:2025-10-01:current:5f15a277b3f97428a1bb0a514f1d6001c62bfcbb4742e1e3e51935a0dae86d50** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30788534/) (`pubmed-observation-pmid-30788534-2025-10-01-5f15a277b3f9`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "MOTS-c: an equal opportunity insulin sensitizer." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30788534-mots-c-v1.json SHA-256: ec7c699ec4d4fc1570d20b2d26b050ccfaaf8911472cba2cd87a4f4b7769878f.